New machine learning model could help pinpoint stages of Parkinson’s

News

Author: Sophie BatesPublished: 13 August 2020

Prep: Cook: Serves:

A new machine learning model aims to help clinicians understand how Parkinson’s progresses in an individual, in relation to the emergence of symptoms of the condition.

The model, designed by US technology company IBM in collaboration with US charity The Michael J Fox Foundation (MJFF), assesses how advanced an individual’s Parkinson’s is – and takes into consideration how medication may mask visible symptoms such as tremors. Researchers at IBM plan to train the model using data from people with Parkinson’s, collected by MJFF, to help define each stage of the condition.

Kristen Severson, a postdoctoral researcher at IBM Research said: “In the future, progression models such as ours may help support various clinical applications. For example, once the disease states are learned, clinicians could quantitatively group patients as well as better predict progression – which could potentially help to inform more personalised patient care and management, as well as more effective drug trials.”

To read more on this topic click here.

For more information on the latest Parkinson’s research please visit the Parkinson’s Europe website.

US hospital initiative improves on-time administration of Parkinson’s medication

Last Month

Next Month

Go Back

Share this story

Comments

Interviews

Parkinson’s and end-of-life: “I’m not afraid of dying”

Eleonor Högström on end-of-life preparations

How does the impact of DBS vary across Parkinson’s disease subtypes?

Exploring the treatment’s effect on non-motor symptoms

Fast-acting inhalable levodopa produces positive results in clinical trial

Is inhalable levodopa for treating Parkinson’s one step closer?

35 new Parkinson’s drug trials launched in last year

Researchers launched 35 new clinical trials of Parkinson’s drug therapies in the last year, according to recent findings published in the ‘Journal of Parkinson’s Disease’. The 2023 Parkinson’s drug development pipeline report noted a slight decrease in active trials compared to the 2022 update (down from 147 to 139 overall). About one-third of trials were still in Phase 1, half were in Phase 2 – and just 20 (14%) were in Phase 3, raising concerns about ‘slow progress’. However, of the active trials logged on ClinicalTrials.gov at the time of the latest report, 35 were found to be newly registered. The report authors concluded: “The slow progress and lack of agents transitioning from Phase 2 to Phase 3 is concerning, but collective efforts by various stakeholders are being made to accelerate the clinical trial process, with the aim of bringing new therapies to the [Parkinson’s] community sooner.”

Parkinson’s Europe co-founder Lizzie Graham wins World Parkinson Coalition award

Parkinson’s Europe co-founder Lizzie Graham has won a World Parkinson Coalition (WPC) award for her contribution to the Parkinson’s community. Lizzie is one of four people set to receive the Robin Elliott Award – which is given out every three years to individuals whose efforts best embody the goals and ethos of the WPC. She will be presented with the award in a ceremony at the World Parkinson’s Congress, which will be held in Barcelona later this year. Commenting on the news of Lizzie’s award, Parkinson’s Europe President, Veronica Clark, said: “Lizzie is Lizzie, and we love her for who she is and what she has done for us all – for people with Parkinson’s past and present and, I’m sure, future.” Lizzie co-founded the European Parkinson’s Disease Association (renamed Parkinson’s Europe last year) in 1992. She has since held several roles within the organisation – including secretary general and…

Study explores predictors of cognitive impairment in Parkinson’s disease

Cognitive impairment can affect some people with Parkinson’s – and may greatly impact their quality of life. Now, researchers in China have examined the possible risk factors for cognitive impairment in those with the condition. The study analysed data from 409 people with Parkinson’s within two years of their involvement in the Parkinson’s Progression Markers Initiative (PPMI) – an international study that follows people with and without the condition over time. The participants, who were newly diagnosed and experiencing normal cognitive function at the start of the research, were studied for at least five years. Published in ‘Frontiers in Aging Neuroscience’, the results indicate that older age at onset, high blood pressure and worse baseline motor symptoms may be among factors that could contribute to an increased risk of developing cognitive impairment. The researchers cautioned that “a larger sample and much more comprehensive assessment, and prolonged follow-up, will be required”.

All fields required

First name*
Last name*
Email address*
Enter Email Confirm Email
Country of residence*
About me*
- I have Parkinson's disease
- I am a partner / carer / family / friend of someone who has Parkinson's
- I am a healthcare professional with an interest in Parkinson's
- I work for a Parkinson's disease organisation
- Other
CAPTCHA
*
- By proceeding you agree to our
Email
This field is for validation purposes and should be left unchanged.

New machine learning model could help pinpoint stages of Parkinson’s

News

Author: Sophie BatesPublished: 13 August 2020

Prep: Cook: Serves:

Last Month

Next Month

Share this story

Comments

Interviews

Parkinson’s and end-of-life: “I’m not afraid of dying”

Global update

How does the impact of DBS vary across Parkinson’s disease subtypes?

Advances

Fast-acting inhalable levodopa produces positive results in clinical trial

35 new Parkinson’s drug trials launched in last year

Parkinson’s Europe co-founder Lizzie Graham wins World Parkinson Coalition award

Study explores predictors of cognitive impairment in Parkinson’s disease

{title}

Subscribe

New machine learning model could help pinpoint stages of Parkinson’s

News

Author: Sophie BatesPublished: 13 August 2020

Last Month

Next Month

Share this story

Comments

Related articles

Interviews

Parkinson’s and end-of-life: “I’m not afraid of dying”

Global update

How does the impact of DBS vary across Parkinson’s disease subtypes?

Advances

Fast-acting inhalable levodopa produces positive results in clinical trial

35 new Parkinson’s drug trials launched in last year

Parkinson’s Europe co-founder Lizzie Graham wins World Parkinson Coalition award

Study explores predictors of cognitive impairment in Parkinson’s disease

{title}

Subscribe

Sign in